view solid quarter slight beat top
bottom-lin new ceo noel wallac confid cl
momentum continu step back
bigger pictur remain quit mix cl organ sale
growth improv sequenti share loss continu
 global gross margin contract miss
consensu deceler sequenti
absolut y/i basi price confusingli also
slow like due increas promo ad spend
materi cost cl drive growth
help support top-lin also pressur ep guidanc
remain -msd all-in still lot work
fundament becom harder justifi cl elev
valuat view price-to-earnings premium
xlp/ vs year histor averag
maintain market perform rate cl larg cap
hpc prefer pg outperform stronger
organ sale growth deliv margin expans ep
growth price-to-earnings multipl turn cl
ep clean cl report adj ep y/i
ahead consensu estim overal
ebit in-lin forecast like ahead consensu
below-the-lin item drive miss vs
improv growth balanc across volume/pr
geographi categori emerg market growth
acceler remain well behind peer pg
post share loss continu key countri includ
brazil china india toothpast gross margin
remain pressur y/i driven headwind
higher raw materi cost guidanc reiter cl
expect organ sale growth net sale flat lsd gross
margin ep -msd maintain
ep estim rais price target
better expect organ sale growth
earli relaunch track relaunch
colgat total hill scienc diet franchis estimate total
sale respect expect key driver cl organ
sale growth acceler vs
relaunch progress plan
product shelf expand global
includ total relaunch brazil management optimist total
sell-through share last week
though note latest track channel result
less robust see page addit cl increas price via
downsiz packag total price per ounc
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
exclud restructur charg one-tim item
compani data secur llc estim reuter
ep clean cl report adjust ep y/i ahead consensu
estim overal ebit in-lin forecast like ahead
consensu below-the-lin item interest/postretir cost drive miss
vs estim
organ sale growth ahead expect organ sale growth ahead
our/consensu estim improv sequenti vs growth
balanc volum pricing/promo also geograph
balanc develop emerg market categori growth driven
toothpast hill cl post posit organ sale growth categori e-comm
growth particularli strong
addit segment-by-seg data point segment organ sale growth in-lin
beat estim segment latin america vs estimate though oper profit
north america vs flat estimate despit tough y/i
comparison europ vs estimate asia pacif vs estimate africa eurasia
vs estimate hill vs estimate addit segment detail
latin america organ sale growth well ahead estim
strong acceler volum main driver sequenti
improv acceler vs volum brazil notabl
inflect posit nonetheless manag note categori trend brazil appear
improv manag also indic market remain promot price
slow oper profit continu pressur
consecut quarter declin ebit margin y/i
north america organ sale growth ahead flat estim impress
consid cl face tough comparison first quarter cl recent
profession skin care acquisit elta md pca skin includ organ sale growth
addit manag note e-commerc deliv particularli strong toothpast
growth manag also note colgat total relaunch proceed in-lin
expect total market share y/i sinc launch cl took price
downsiz manag hope lead shorter repurchas cycl
potenti acceler unit growth go forward growth balanc volum
price/promo howev share loss continu cl lose
share toothpast manual toothbrush north american oper profit
ebit margin y/i
europ organ sale growth remain mute though ahead
estim volum price remain pressur
manag call strong volum growth northern europ uk scandinavia
back colgat total relaunch quarter cl gain toothpast
share itali switzerland among countri oper incom
ebit margin y/i
asia pacif organ sale growth in-lin estim
overal net sale volum price flat fx
headwind volum declin greater china partial off-set volum gain
india australia thailand philippin cl result china remain challeng
step cl taken reorient compani portfolio oral rapidli
premium shift e-commerc said cl still expect trend improv
elsewher cl saw strong growth volum price india growth come
colgat maxfresh colgat vedshakti franchis oper profit
africa eurasia organ sale growth in-lin estim overal
net sale volum flat y/i price fx
headwind volum gain russia gulf state off-set volum declin south
africa saudi arabia oper profit basi
final hill organ sale growth robust vs estim overal net
sale volum price fx
volum gain western europ partial off-set volum declin south
africa russia oper profit flat y/i y/i
share loss continu cl global toothpast share y/i vs
manual toothbrush share vs last year
 cl toothpast share manual toothbrush share
share loss also continu key countri includ brazil
china india
price take glass half full approach admittedli found odd
pricing/promo slow vs forecast price
substanti overal manag upbeat composit cl net sale
growth quarter cl deliv volum price growth first time
two year volum price four cl categori oral pet nutrit
 cl took price via downsiz price per ounc colgat
total manag believ lead shorter repurchas cycl look
forward manag also believ price product program off-set increas
raw materi cost includ impact transact fx manag also note
cl price still yet come third go furthermor spot rate
chang also expect take price said given price mute vs
expect quarter continu take wait see approach becom
increment posit cl price outlook
gross margin remain pressur all-in gross margin y/i
estim overal compani price quarter provid
basis-point lift gross margin off-set howev higher raw materi cost incl fx
transact cost drag gross margin elsewher cl product
program led long-standing fund growth initi provid lift gross
margin drag all-in cl manag still expect gross margin
non-gaap basi ex charg relat global growth effici program
although interestingli manag comment convers back away
compani prior gross margin target cl expect benefit price
product off-set overal increas raw materi cost incl transact fx all-in
pleas gross margin still like posit y/i also somewhat
cogniz larg driven cost save less price short
case cl price initi also take wait-and-se approach compani
margin cogniz like plenti put take respect cl
margin balanc year
guidanc larg maintain manag continu call organ
sale growth net sale growth flat lsd gross margin still expect y/i
although manag didnt explicitli comment compani previous disclos
target elsewher cl expect advertis spend notabl y/i absolut basi
percent sale advertis percent sale full year fairli consist
advertis level final manag continu expect ep declin -msd
compani report secur llc
market growth soft past sever quarter cosmet household person
exhibit cl organ sale segment
compani report secur llc estim
exhibit cl ebit segment
compani report secur llc
background total relaunch
total relaunch receiv record brand support cl also take price total one cl
largest brand sale manag character relaunch
biggest news brand year histori manag expect relaunch accomplish
host lofti object includ reinvigor brand drive stepped-up custom
engag increas trial/market share cl support launch record amount
market support includ in-stor display promot influenc super bowl ad
accord manag product advertis test gone extrem well retail
commit remark on-shelf support importantli cl simultan take higher price
relaunch view part cl broader push innov premium across
new formul culmin multi-year process total compet multi-benefit
segment toothpast categori given size/success total manag hesit
chang formula unless truli provid better technolog accord cl new
formul culmin develop hold patent anoth
patent pend new colgat total contain benefit old formul antibacteri
plaqu gingiv caviti whiten tartar enamel protect breath also ad host
new benefit includ anti-sensit instant neutral odor increment enamel
protect new flavor importantli new formula also remov triclosan key ingredi
view posit given controversi surround triclosan think cl
made chang year ago
work minim risk relaunch total relaunch shelf februari
roll global manag continu view transit
soft launch replac new total old formul sold time
hope minim risk cl take back old inventori said cl take
step minim disrupt still view execut risk heighten given size brand
logist complex cl wide divers global distribut network
size total
colgat total brand share global higher share sever cl key market
includ share brazil share
 track channel colgat total hold share total brand retail sale
repres cl toothpast sale total sale slow begin
late week end
total share also weak march
recent weak result may driven pullback promot ahead relaunch promo
normal last two month sale promo march
wk
volum price sale growth
sold promo
chart tabl nielsen xaoc includ c-store secur llc
meanwhil toothpast categori also slow track channel
categori sale rang seen categori
growth also deceler late improv week end
categori promot deceler materi begin mid-
last month
cl share toothpast track channel cl overal toothpast sale growth
lag categori result share march
chang bp dollar chang bp sold promo colgate-palmol compani
toothpast volum average price/unit growth
toothpast categori sold promo
chart nielsen xaoc includ c-store secur llc
sale y/yeq sale y/yavg eq price y/i sold promo dollar sharedollar share y/i bp retailperiod end end end end end end procter gambl compani smith kline dwight compani channel data chang bp sold promo cosmet household person
histor track record stabil immun macroeconom volatil cl one
world recogniz consum product compani oral care person care home care
pet nutrit product purchas two-third world household
compani global well ahead ko believ cl well-posit
long-term given unmatch distribut platform across emerg market net sale
per-capita outpac develop market long-stand track record
achiev product save cost effici expect compani fund growth cost-
save program remain import contributor gross margin estim individu
contribut gross margin basi point bp annual next sever year
reflect increasingli streamlin global manufactur footprint continu invest
rigor analyt capabl said cl top-lin growth slow materi past
year particularli emerg market believ cl face macroeconomic
competit pressur across global oper previous result see multi-year
period increas invest cl need step invest improv top-lin trajectori
believ dynam like pressur margin could reduc cl long-term ep growth potenti
view cl histor track record oper stabil favor see dynam
competit environ look forward therefor maintain market perform rate
price target base follow methodolog forward ev-to-ebitda price-to-earnings
analysi absolut rel discount cash flow analysi
forward ev-to-ebitda absolut rel cl current trade ev/ebitda
multipl premium compani histor averag multipl
premium compani histor averag multipl rel peer
cl current trade discount rel hpc peer group discount rel
mega-cap peer forward ev/ebitda multipl basi compar discount
hpc/mega-cap group histor averag forward ev/ebitda basi
discount hpc/mega-cap group histor averag forward ev/ebitda basi price
colgate-palmol compani cl financi guidanc secur llcbonni herzog except per-shar data sourc tabl compani report secur llc estimatesguid provid januari call april call fy fy sale salesflat lsdflat margin bp vs ly bp vs ly bp vs ly bp vs ly growth growth provid januari call april call juli call octob call fy sale growth lsd-msd margin bp vs ly rel absolutelyup rel absolutelyup rel bp vs ly growth dollar basi ldd around around end guidancefi guidanc colgate-palmol compani
target impli ev-to-ebitda multipl discount compani current
forward multipl premium premium histor averag
forward ev-to-ebitda multipl believ appropri consid cl recent top-lin
margin challeng elev competit environ key emerg market
forward price-to-earnings absolut rel cl current trade price-to-earnings multipl
premium compani histor averag multipl premium
compani histor averag multipl rel peer cl current trade
premium rel hpc peer group premium rel mega-cap peer
forward price-to-earnings multipl basi compar premium hpc/mega-cap group
year histor averag forward price-to-earnings basi premium hpc/mega-cap group
year histor averag forward price-to-earnings basi price target impli price-to-earnings multipl
discount compani current forward multipl premium
discount histor averag forward price-to-earnings multipl
sum-of-the-part discount also valu cl base sum-of-the-part dcf
analysi appropri valu specif opportun cl differ segment base
analysi believ cl worth north america segment worth europ
segment worth latin america segment worth asia pacif segment worth
africa eurasia segment worth pet nutrit segment worth
chart factset secur llc
factset secur llc
compani cl earn varianc sheet secur llcbonni herzog except per-shar data report changenorth profit- inc oper ens relat postretir attribut non-control incom minor share eps- changegross margin normal margin normal compani report secur llc estimatesactu vs estimateactu vs estimateyear/year changesequenti changeyear/year changesequenti chang compani
compani report secur llc estim
colgate-palmol compani cl quarterli earn secur llcbonni herzog except per-shar data sourc tabl compani report secur llc profit- inc oper ens relat postretir attribut non-control incom minor share eps- eps- per america ex ex america ex pacif ex ex ex net net sale ex ex percent salescost good revenu build unless sale stack organ sale colgate-palmol compani
compani report secur llc estim
segment data net organ sale unless note north salesnorth sale ex-currencynorth sale growthnorth sale growth ex-currencynorth net salesnorth data incomenorth segment net segment ebitnorth ebit marginnorth cosmet household person
cl volum average price/unit growth y/i
cl dollar share y/i chang
chart nielsen xaoc includ c-store secur llc
note nielsen quarter-to-d data repres simpl averag nielsen data period follow last period
compani report nielsen xaoc includ c-store secur llc estim
sale y/yeq sale y/yavg eq price y/i sold promo sold promo y/ydollar sharedollar share y/i bp retailperiod end end end end end end end soap-light combin channel data chang bp dollar quarterli north america segment organ sale performanceconsum take-away retail vs manufactur shipment report nielsenreported/estimatedcorrel colgate-palmol compani
exhibit cl european summari data week end
cl european eq volum average price/eq growth y/i
cl european valu share y/i chang
nielsen esp total europ secur llc
nielsen esp total europ secur llc estim
exhibit cl categori result period end
nielsen scantrack total emerg market secur llc
exhibit cl emerg market valu sale volum average price per growth
nielsen scantrack total emerg market secur llc
note growth rate exclud brazil prior
exhibit cl emerg market valu share y/i chang
nielsen scantrack total emerg market secur llc
price target
price target assum price-to-earnings ev-to-ebitda multipl risk price
target includ increment fx headwind local brand competit materi slowdown emerg
cl one attract geograph profil core hpc stapl view said
weak growth stepped-up invest spend give us paus
co base new york new york lead consum product compani
produc market oral care home care person care pet nutrit product compani
signific intern presenc market product countri territori world-wide
brand portfolio includ namesak colgat palmol brand also includ number
global brand includ ajax irish spring hill scienc diet softsoap speed stick suavitel
tom main www colgat com
pg thesi pg chang sens urgenc account infus
organ pg fundament improv compani gener consist result
see pg one stapl compani abl consist deliv
acceler organ sale growth time expand margin
